^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MRT-2359

    i
    Other names: MRT-2359, GSPT1-directed MGD
    Company:
    Monte Rosa Therap
    Drug class:
    GSPT1 degrader
    Related drugs:
    almost2years
    Study of Oral MRT-2359 in Selected Cancer Patients (clinicaltrials.gov)
    P1/2, N=135, Recruiting, Monte Rosa Therapeutics, Inc
    Trial completion date • Trial primary completion date
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
    |
    MYCN amplification • MYC expression
    |
    MRT-2359
    3years
    Study of Oral MRT-2359 in Selected Cancer Patients (clinicaltrials.gov)
    P1/2, N=133, Recruiting, Monte Rosa Therapeutics, Inc | Not yet recruiting --> Recruiting
    Enrollment open
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
    |
    MYCN amplification • MYC expression
    |
    MRT-2359
    3years
    Study of Oral MRT-2359 in Selected Cancer Patients (clinicaltrials.gov)
    P1/2, N=133, Not yet recruiting, Monte Rosa Therapeutics, Inc
    New P1/2 trial
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
    |
    MYCN amplification • MYC expression
    |
    MRT-2359